Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Regulation of protumorigenic pathways by Insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis

Authors: Priyanka Sehgal, Neeraj Kumar, Varuvar Rajesh Praveen Kumar, Shilpa Patil, Animesh Bhattacharya, Manavalan Vijaya Kumar, Geetashree Mukherjee, Paturu Kondaiah

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Insulin like growth factor binding proteins modulate the mitogenic and pro survival effects of IGF. Elevated expression of IGFBP2 is associated with progression of tumors that include prostate, ovarian, glioma among others. Though implicated in the progression of breast cancer, the molecular mechanisms involved in IGFBP2 actions are not well defined. This study investigates the molecular targets and biological pathways targeted by IGFBP2 in breast cancer.

Methods

Transcriptome analysis of breast tumor cells (BT474) with stable knockdown of IGFBP2 and breast tumors having differential expression of IGFBP2 by immunohistochemistry was performed using microarray. Differential gene expression was established using R-Bioconductor package. For validation, gene expression was determined by qPCR. Inhibitors of IGF1R and integrin pathway were utilized to study the mechanism of regulation of β-catenin. Immunohistochemical and immunocytochemical staining was performed on breast tumors and experimental cells, respectively for β-catenin and IGFBP2 expression.

Results

Knockdown of IGFBP2 resulted in differential expression of 2067 up regulated and 2002 down regulated genes in breast cancer cells. Down regulated genes principally belong to cell cycle, DNA replication, repair, p53 signaling, oxidative phosphorylation, Wnt signaling. Whole genome expression analysis of breast tumors with or without IGFBP2 expression indicated changes in genes belonging to Focal adhesion, Map kinase and Wnt signaling pathways. Interestingly, IGFBP2 knockdown clones showed reduced expression of β- catenin compared to control cells which was restored upon IGFBP2 re-expression. The regulation of β-catenin by IGFBP2 was found to be IGF1R and integrin pathway dependent. Furthermore, IGFBP2 and β-catenin are co-ordinately overexpressed in breast tumors and correlate with lymph node metastasis.

Conclusion

This study highlights regulation of β-catenin by IGFBP2 in breast cancer cells and most importantly, combined expression of IGFBP2 and β-catenin is associated with lymph node metastasis of breast tumors.
Appendix
Available only for authorised users
Literature
1.
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E: Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res. 2001, 61: 8601-8610.PubMed
2.
Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W: Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999, 59: 4228-4232.PubMed
3.
Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003, 63: 4315-4321.PubMed
4.
Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000, 60: 6617-6622.PubMed
5.
Wang H, Rosen DG, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 2006, 19: 1149-1156. 10.1038/modpathol.3800637CrossRefPubMed
6.
Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997, 82: 2308-2313. 10.1210/jc.82.7.2308PubMed
7.
Chen R, Pan S, Yi EC, Donohoe S, Bronner MP, Potter JD, Goodlett DR, Aebersold R, Brentnall TA: Quantitative proteomic profiling of pancreatic cancer juice. Proteomics. 2006, 6: 3871-3879. 10.1002/pmic.200500702CrossRefPubMed
8.
Zhang L, Huang W, Chen J, Zhou X, Lu Z, Zhou H: Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation. Dig Dis Sci. 2007, 52: 248-253. 10.1007/s10620-006-9358-zCrossRefPubMed
9.
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993, 77: 229-233. 10.1210/jc.77.1.229PubMed
10.
Mishra L, Bass B, Ooi BS, Sidawy A, Korman L: Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res. 1998, 8: 473-479. 10.1016/S1096-6374(98)80300-6CrossRefPubMed
11.
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M: Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008, 14: 6944-6954. 10.1158/1078-0432.CCR-08-0408CrossRefPubMed
12.
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005, 58: 361-366. 10.1136/jcp.2004.020834PubMedCentralCrossRefPubMed
13.
Wex H, Vorwerk P, Mohnike K, Bretschneider D, Kluba U, Aumann V, Blum WF, Mittler U: Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer. 1998, 78: 515-520. 10.1038/bjc.1998.525PubMedCentralCrossRefPubMed
14.
van der Laan BF, Freeman JL, Asa SL: Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid. 1995, 5: 67-73. 10.1089/thy.1995.5.67CrossRefPubMed
15.
McDonald KL, O’Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ: IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol. 2007, 66: 405-417. 10.1097/nen.0b013e31804567d7CrossRefPubMed
16.
Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Zhang W, Song SW: Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. 2009, 11: 468-476. 10.1215/15228517-2008-114PubMedCentralCrossRefPubMed
17.
Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS, Lin JT: Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010, 95: 1717-1725. 10.1210/jc.2009-2668CrossRefPubMed
18.
Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L: Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol. 2005, 47: 695-702. 10.1016/j.eururo.2004.12.015CrossRefPubMed
19.
Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P: Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer. 2003, 105: 14-19. 10.1002/ijc.11015CrossRefPubMed
20.
Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM: Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011, 104: 1587-1593. 10.1038/bjc.2011.127PubMedCentralCrossRefPubMed
21.
Hoeflich A, Yang Y, Huber S, Rascher W, Koepf G, Blum WF, Heinz-Erian P, Kolb HJ, Kiess W: Expression of IGFBP-2, -3, and −4 mRNA during differentiation of Caco-2 colon epithelial cells. Am J Physiol. 1996, 271: E922-E931.PubMed
22.
Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL: The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab. 1996, 81: 3709-3716. 10.1210/jc.81.10.3709PubMed
23.
Birnbaum RS, Wiren KM: Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology. 1994, 135: 223-230. 10.1210/en.135.1.223PubMed
24.
Chakrabarty S, Kondratick L: Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 2006, 5: 189-197. 10.4161/cbt.5.2.2333CrossRefPubMed
25.
Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H: Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007, 282: 18634-18644. 10.1074/jbc.M609567200CrossRefPubMed
26.
Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer. 2005, 4: 7- 10.1186/1476-4598-4-7PubMedCentralCrossRefPubMed
27.
Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 2005, 13: 341-345.PubMed
28.
Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 2007, 104: 11736-11741. 10.1073/pnas.0703145104PubMedCentralCrossRefPubMed
29.
Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M: Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc Natl Acad Sci USA. 2012, 109: 3475-3480. 10.1073/pnas.1120375109PubMedCentralCrossRefPubMed
30.
Wang GK, Hu L, Fuller GN, Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 2006, 281: 14085-14091. 10.1074/jbc.M513686200CrossRefPubMed
31.
Wang H, Arun BK, Fuller GN, Zhang W, Middleton LP, Sahin AA: IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008, 14: 261-267. 10.1111/j.1524-4741.2008.00572.xCrossRefPubMed
32.
Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW: IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol. 2006, 37: 13-23. 10.1677/jme.1.01955CrossRefPubMed
33.
Hoflich A, Lahm H, Blum W, Kolb H, Wolf E: Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett. 1998, 434: 329-334. 10.1016/S0014-5793(98)01011-4CrossRefPubMed
34.
Ueno K, Hirata H, Majid S, Tabatabai ZL, Hinoda Y, Dahiya R: IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int J Cancer. 2011, 129: 2360-2369. 10.1002/ijc.25899CrossRefPubMed
35.
Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature. 2005, 434: 843-850. 10.1038/nature03319CrossRefPubMed
36.
Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A: Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol. 2006, 19: 556-563. 10.1038/modpathol.3800562CrossRefPubMed
37.
Gavert N, Ben-Ze’ev A: beta-Catenin signaling in biological control and cancer. J Cell Biochem. 2007, 102: 820-828. 10.1002/jcb.21505CrossRefPubMed
38.
Takahashi-Yanaga F, Kahn M: Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin Cancer Res. 2010, 16: 3153-3162. 10.1158/1078-0432.CCR-09-2943CrossRefPubMed
39.
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000, 97: 4262-4266. 10.1073/pnas.060025397PubMedCentralCrossRefPubMed
40.
Brembeck FH, Rosario M, Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006, 16: 51-59. 10.1016/j.gde.2005.12.007CrossRefPubMed
41.
42.
Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA: Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997, 99: 1390-1398. 10.1172/JCI119298PubMedCentralCrossRefPubMed
43.
44.
Andersson S, D’Arcy P, Larsson O, Sehat B: Focal adhesion kinase (FAK) activates and stabilizes IGF-1 receptor. Biochem Biophys Res Commun. 2009, 387: 36-41. 10.1016/j.bbrc.2009.06.088CrossRefPubMed
45.
Png KJ, Halberg N, Yoshida M, Tavazoie SF: A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011, 481: 190-194. 10.1038/nature10661CrossRefPubMed
46.
Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988, 55: 619-625. 10.1016/0092-8674(88)90220-6CrossRefPubMed
47.
Khan I, Agarwal P, Thangjam GS, Radhesh R, Rao SG, Kondaiah P: Role of TGF-beta and BMP7 in the pathogenesis of oral submucous fibrosis. Growth Factors. 2011, 29: 119-127. 10.3109/08977194.2011.582839CrossRefPubMed
48.
Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK: A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007, 23: 2700-2707. 10.1093/bioinformatics/btm412CrossRefPubMed
49.
Smyth GK, Speed T: Normalization of cDNA microarray data. Methods. 2003, 31: 265-273. 10.1016/S1046-2023(03)00155-5CrossRefPubMed
50.
Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3-PubMed
51.
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M: TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003, 34: 374-378.PubMed
52.
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D: Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011, 10: 188-193. 10.1016/j.clcc.2011.03.014CrossRefPubMed
Metadata
Title
Regulation of protumorigenic pathways by Insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis
Authors
Priyanka Sehgal
Neeraj Kumar
Varuvar Rajesh Praveen Kumar
Shilpa Patil
Animesh Bhattacharya
Manavalan Vijaya Kumar
Geetashree Mukherjee
Paturu Kondaiah
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-63

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes

Research

The Wilms’ tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells

Research

Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling

Research

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway

Short communication

POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15)

Research

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits